The approval from the sponsor Astellas Pharma, Japan, was received for the Site's participation in a randomized, double-blind, placebo-controlled 24-week phase 3b study to study a new medicine for the elimination of moderate and severe vasomotor symptoms (hot flashes) in postmenopausal women for whom hormone replacement therapy is unacceptable.
